References
- Soto-Perez-de-Celis E , LiD, YuanY, LauYM, HurriaA. Functional versus chronological age: geriatric assessments to guide decision making in older patients with cancer. Lancet Oncol.19(6), e305–e316 (2018).
- Pallis AG , FortpiedC, WeddingUet al. H. EORTC elderly task force position paper: approach to the older cancer patient. Eur. J. Cancer46(9), 1502–1513 (2010).
- Hurria A , LevitLA, DaleWet al. Improving the evidence base for treating older adults with cancer: American Society of Clinical Oncology statement. J. Clin. Oncol.33(32), 3826–3833 (2015).
- Kanesvaran R , CordobaR, MaggioreR. Immunotherapy in older adults with advanced cancers: implications for clinical decision-making and future research. Am. Soc. Clin. Oncol. Educ. Book.38, 400–414 (2018).
- Müller L , DiBenedetto S, PawelecG. The immune system and its dysregulation with aging. Subcell Biochem.91, 21–43 (2019).
- Wagner A , Garner-SpitzerE, JasinskaJet al. Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci. Rep.8(1), 9825 (2018).
- Nishijima TF , MussHB, ShacharSS, MoschosSJ. Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: a systematic review and meta-analysis. Cancer Treat. Rev.45, 30–37 (2016).
- Elias R , Giobbie-HurderA, McClearyNJ, OttP, HodiFS, RahmaO. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. J. Immunother. Cancer6(1), 26 (2018).
- Kasherman L , SiuDHW, LeeKWCet al. Efficacy of immune checkpoint inhibitors in older adults with advanced stage cancers: a meta-analysis. J. Geriatr. Oncol.11(3), 508–514 (2019).
- Grossi F , GenovaC, CrinòLet al. Real-life results from the overall population and key subgroups within the Italian cohort of nivolumab expanded access program in non-squamous non-small cell lung cancer. Eur. J. Cancer123, 72–80 (2019).
- Youn B , TrikalinosNA, MorV, WilsonIB, DahabrehIJ. Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer. Cancer126(5), 978–985 (2020).
- Wang Y , ZhouS, YangFet al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: a systematic review and meta-analysis. JAMA Oncol.5(7), 1008–1019 (2019).
- Wang DY , SalemJE, CohenJVet al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol.4(12), 1721–1728 (2018).
- Corbaux P , MailletD, BoespflugAet al. Older and younger patients treated with immune checkpoint inhibitors have similar outcomes in real-life setting. Eur. J. Cancer121, 192–201 (2019).
- Ridolfi L , DeRosa F, PetracciEet al. Anti-PD1 antibodies in patients aged ≥75years with metastatic melanoma: a retrospective multicentre study. J. Geriatr. Oncol.doi: S1879-4068(19)30356-X (2020). [ Epub Ahead of Print]
- Spigel D , SchwartzbergL, WaterhouseDet al. Is nivolumab safe and effective in elderly and PS2 patients with non-small cell lung cancer (NSCLC)? Results of checkMate 153: topic: IT. J. Thorac. Oncol.12(1), S1287–S1288 (2017).
- van Holstein Y , KapiteijnE, BastiaannetEet al. Efficacy and adverse events of immunotherapy with checkpoint inhibitors in older patients with cancer. Drugs Aging36(10), 927–938 (2019).